Peer Exchange

The Evolving Treatment Landscape of Small Cell Lung Cancer

June 27th 2022

A panel of experts discuss how recent data from ASCO 2022 has changed the treatment landscape for small cell lung cancer.

Updates in the Treatment of HER2+ and HER2-Low Breast Cancer

June 27th 2022

Expert oncologists Andy Seidman, MD; Vijayakrishna Gadi, MD, PhD; Tiffany Traina, MD; William Gradishar, MD; and Stephanie Graff, MD, review data from ASCO 2022 and share updates in the management of HER2+ and HER2-low breast cancer.

Therapy Options in HR+/HER2- Breast Cancer

June 27th 2022

Expert oncologists Hope S. Rugo, MD, FASCO; Aditya Bardia, MD, MPH; Komal Jhaveri, MD, FACP; Mark Pegram, MD; and Anne O'Dea, MD, review data from recent conferences and discuss updates in the management of HR+/HER2- breast cancer.

Actionable Mutations in NSCLC: Expert Perspectives in Testing and Targeted Therapy

April 12th 2022

A panel of expert oncologists discusses updates in advanced non-small cell lung cancer and the evolving treatment landscape, and its impact on clinical practice.

Patient Profiles in HER2-Positive Breast Cancer

March 31st 2022

Experts engage in discussion on patient profiles to review updated treatment approaches and sequencing in patients with HER2-positive metastatic breast cancer.

Recent Advances in the Treatment of Prostate Cancer

March 31st 2022

Expert panelists share insight on recent updates in the management of prostate cancer presented at several key conferences.

Evidence-Based Strategies for Selecting and Sequencing Systemic Therapies in RCC: Highlights From ASCO GU 2022 and Beyond

March 15th 2022

A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.

A New Wave of Progress in the Treatment of Hepatocellular Cancer

March 9th 2022

Experts in gastrointestinal cancers review recent updates to the treatment landscape of advanced HCC and share insights on their impact on clinical practice.

The Changing Treatment Paradigm of HER2+ Metastatic Breast Cancer

January 26th 2022

Expert panelists reflect on the evolving landscape of HER2+ metastatic breast cancer by discussing the latest research and recent clinical trials.

Recent Advances in the Treatment of Chronic Lymphocytic Leukemia

January 24th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Advances in the Management of Graft Versus Host Disease

January 11th 2022

Yi-Bin Chen, MD; Nelson J. Chao, MD, MBA; Hannah Choe, MD; and Sophie Paczesny, MD, PhD, review updates in the diagnosis and treatment of graft-vs-host disease.

Myeloproliferative Neoplasms

December 23rd 2021

A panel of experts discuss myeloproliferative neoplasms, focusing primarily on myelofibrosis, and share their experiences treating these diseases.

Navigating New Treatment Options in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

December 23rd 2021

A panel discussion on changing treatment landscape of diffuse large B-cell lymphoma (DLBCL) and how new data from ASH 2021 on CAR-T therapies and antibody-drug conjugate are likely to change frontline treatment and sequencing of therapies in relapsed and refractory DLBCL going forward.

Updates in the Treatment of B-cell Lymphoma: Focus on Mantle Cell Lymphoma, Follicular Lymphoma, and Marginal Zone Lymphoma

December 23rd 2021

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Antibody-Drug Conjugates in Breast Cancer: Strategies for Toxicity Management

December 23rd 2021

Recommendations for treating 2 clinical cases of metastatic breast cancer with antibody-drug conjugates based on supporting data and their adoption into clinical practice.

Funding from Daiichi Sanyko. Content Developed Independently by OncLive.

Global Perspectives in the Treatment of EGFR-mutant Resectable and Advanced NSCLC

December 22nd 2021

Expert perspectives on updates in EGFR-mutant resectable and advanced non–small cell lung cancer that were presented at key conferences in 2021 and how they have impacted the treatment landscape.

Recent Advances in the Treatment of Relapsed/Refractory Multiple Myeloma

December 22nd 2021

Experts in hematology/oncology review recent updates in the treatment of multiple myeloma presented at key conferences and share insight on the impact on clinical practice.

The Evolving Landscape of Differentiated Thyroid Cancer Treatment

December 17th 2021

Medical oncologists and endocrinologists discuss approaches to the management of patients with differentiated thyroid cancer.

Treatment Approaches in Non-Melanoma Skin Cancers

November 22nd 2021

A panel of experts discuss basal cell carcinoma and cutaneous squamous cell carcinoma therapeutic agents in depth as they analyze clinical case scenarios.

Emerging Treatment Considerations in Hepatocellular Carcinoma: An Expert Case-based Discussion

November 10th 2021

Experts in gastroenterology provide insight on various case studies and the optimal treatment approaches for the management of HCC.